• Management

    • Michiel Lodder, PhD – CEO

      Michiel Lodder has served as Chief Executive Officer of 20Med Therapeutics since 2016. Prior to joining he was responsible for corporate and business development at Lanthio Pharma which was acquired by MorphoSys AG in 2015. Before that he was CBO at Pepscan Therapeutics and from 2006 to 2009 managing director of OctoPlus Inc, the Boston based US subsidiairy of OctoPlus NV. Michiel holds a PhD in bioorganic chemistry from the University of Virginia and a MSc from Leiden University.
    • Jaap Rip, PhD - VP R&D

      Jaap Rip is VP R&D at 20Med Therapeutics. Prior to joining 20Med, Jaap held leadership positions at Nanomi BV, Eyesiu Medicines BV and BBB Therapeutics. He is trained as a Biologist at Wageningen University and obtained a PhD at the Amsterdam Medical Center (AMC). Jaap has a specific focus on the preclinical development, scale-up and manufacturing of complex injectable formulations with a strong background in polymer and lipid based (nano)particles for sustained release and targeted drug delivery.
  • Supervisory Board & Advisors

    • Tom Schwarz - Chairman

      After obtaining a degree in Pharmacy from the Utrecht University, Tom (1954) joined Interpharm, a national Pharmaceutical wholesale company as pharmacist and marketing manager. He co-founded and was CEO of U-Gene Research, a Clinical Research Organization. In 1997 U-Gene successfully was sold to Kendle USA, which combination was listed on the Nasdaq in 2007. Tom co-founded Life Sciences Partners in Amsterdam. As general partner Tom sourced, financed and exited many life sciences companies in Europe and the USA. After 2006, Tom concentrated on financing and setting up early stage venture capital companies in the Netherlands. He co-founded the Erasmus Biomedical Fund, Life Sciences Fund Amsterdam and Twente Technology Fund. In 2017 Tom co-founded Innovation Industries.
    • Jean-Paul Prieels - Board Member

      Jean-Paul Prieels is a member of the board of 20Med Therapeutics since 2021. Dr. Prieels holds a PhD in Biochemistry from Université Libre de Bruxelles in Belgium. After ten years in the academic world, ( ULB, ICP-UCL, Duke University) he started his industrial career at Petrofina in 1983 as Biotechnology Manager and joined GlaxoSmithKline Biologicals in 1987. His responsibilities gradually expanded from leading the extramural R&D team to becoming responsible for vaccine preclinical research and development activities in Rixensart, Belgium. He retired as Senior Vice President of WW Research & Development in 2011. He was instrumental in the development of several commercially available vaccines, such as Rotarix, Cervarix, Synflorix, and Shingrix. Today, he is member of Supervisory board at Bone Therapeutics, NCardia, Paracrine Biologicals, Quantoom Biosciences, Leukocare and Nouscom. He is also member of the Scientific Advisory Board at Curevac, Icosavax, Imcyse, Vaximm and Bioaster.
    • Michel Baijot - Board Member

      Michel Baijot, Ph.D., has served as board director since 2022. Dr Michel Baijot is board director of Sinovac, White Fund, Radiomics and Flash Therapeutics. He has spent more than 25 years in various executive positions with bioMerieux as Corporate Director Molecular Diagnostics, with Innogenetics as VP of Business Development, with GSK Vaccines as VP of strategy, licensing and M&A, with Janssen Crucell Vaccines as Chief Business Officer, with Serum Institute of India as Executive Director Europe. He has been Chairman of the Belgian Biotech Association for 5 years. Dr Michel Baijot is a chemical engineer and holds a Ph.D. in molecular biology from University of Louvain (Belgium).
    • Prof. Dr. Johan Engbersen - Founder and Advisor

      Johan is the founder of 20Med Therapeutics BV and em. professor of Biomedical Chemistry at the Technical Medical Centre of the University of Twente. His research during the last 15 years has focused on the development of multifunctional nanosystems for controlled drug and gene delivery. Based on an innovative class of highly effective gene delivery carriers developed in his research he founded 20Med Therapeutics in 2011 as a spin-off company of the University of Twente.